Finerenone for Chronic Kidney Disease: What New Trials Show

When Maria, 62, got her latest lab results, her doctor circled a number on the printout — her eGFR, a measure of how well her kidneys filter waste — and told her it had dropped again. Not dramatically, but enough. Maria doesn't have diabetes. She has IgA nephropathy, a kidney condition caused by a protein buildup in the filters of the kidney, and for years her treatment options felt frustratingly limited. "There's not much we can do beyond controlling your blood pressure," her doctor had told her. That conversation, familiar to millions of adults living with chronic kidney disease, may be about to change in a significant way.

In early June 2026, something rare happened in medicine. Three major clinical trials were published simultaneously — one each in the New England Journal of Medicine, The Lancet, and JAMA — all pointing to the same conclusion: finerenone, a drug previously approved only for kidney disease caused by type 2 diabetes, appears to slow kidney decline and reduce the risk of heart failure and death in a far broader population of adults with chronic kidney disease, including those who don't have diabetes at all. The findings were presented at the European Renal Association Congress in Glasgow that same week. Nephrologists described it as a once-in-a-decade moment for the field.

What Is Finerenone and Who Has Been Using It?

Finerenone belongs to a class of drugs called nonsteroidal mineralocorticoid receptor antagonists. That's a mouthful, so here's the short version: it works by blocking a hormone receptor that, when overactivated, drives inflammation and scarring in the kidneys and heart. The drug was first approved by the FDA in 2021, specifically for adults with chronic kidney disease caused by type 2 diabetes — a large population, but still a subset of the roughly 37 million Americans living with CKD in some form. For everyone else with declining kidney function — people like Maria, whose CKD has a different root cause — finerenone simply wasn't on the table.

That's what made June 2026 so significant. Researchers had been asking for years whether finerenone's protective effects might work regardless of what was causing the kidney damage. The answer, it turns out, appears to be yes.

What the Three Trials Actually Found

The centerpiece study, published in the New England Journal of Medicine, was the FIND-CKD trial — the largest Phase III trial to date in adults with non-diabetic CKD. Over 32 months, participants taking finerenone showed significantly slower decline in kidney function compared to those taking a placebo. These were adults whose CKD had nothing to do with diabetes, and yet finerenone still appeared to protect their kidneys meaningfully. For researchers, that was a crucial piece of evidence.

Digging deeper into the FIND-CKD data, a separate analysis published simultaneously in JAMA focused on a subset of patients with glomerular diseases — conditions like IgA nephropathy and focal segmental glomerulosclerosis (FSGS), both of which affect the kidney's filtering units directly. This is exactly the population Maria belongs to. The JAMA analysis found that finerenone reduced the risk of kidney failure or CKD progression by 26% compared to placebo. Perhaps even more striking: it lowered albuminuria — a key marker of kidney damage, essentially protein leaking into the urine — by 42%. That's a substantial shift in a number that doctors watch closely as a sign of how quickly the kidneys are deteriorating.

Then came the big-picture view. The Lancet published the INFINITY pooled analysis, which combined individual patient data from 14,574 participants across three Phase III trials — both diabetic and non-diabetic CKD. The numbers were hard to ignore. Finerenone reduced the risk of kidney failure or CKD progression by 24%. It cut hospitalization for heart failure or cardiovascular death by 20%. And it lowered all-cause mortality — the risk of dying from any cause — by 12%, compared to placebo. What surprised researchers was the consistency of those benefits across different types of CKD, different ages, and different stages of kidney function at the start of the trials.

Why This Matters More After 50

Chronic kidney disease is, in many ways, a condition of midlife and beyond. The kidneys naturally lose some filtering efficiency with age — eGFR tends to decline gradually starting in your 30s and 40s — but CKD accelerates that process in ways that compound over time. By 65, nearly one in three Americans has some degree of kidney function impairment. And because the kidneys and heart are so deeply interconnected physiologically, CKD doesn't stay in the kidneys. It raises the risk of heart failure, cardiovascular events, and death in ways that make it one of the most serious chronic conditions of later life.

Here's the thing: CKD often has no symptoms until it's fairly advanced. Many adults in their 50s and 60s discover it incidentally — through a routine blood test, during a workup for something else, or, like Maria, when a number on a lab report starts trending in the wrong direction. That's one reason these trial results matter so much for this age group specifically. If finerenone can slow the trajectory even modestly over years, the compounding effect on quality of life, hospitalizations, and mortality could be substantial.

For adults managing multiple medications — and many people over 50 are — the logistics of adding a new drug consistently matter just as much as the prescription itself. SteadiDay's free medication reminders feature was designed with exactly this in mind: a simple, customizable prompt that fits into your day without adding stress. Consistency with a kidney-protective medication isn't a small thing. It's where the clinical benefit actually lives.

What You Should Ask Your Doctor

These findings don't mean finerenone is right for everyone with CKD — and it's not yet approved beyond its current diabetic indication, meaning expanded use will depend on regulatory review following these trials. But the evidence is now substantial enough that it's worth bringing up with your nephrologist or primary care doctor, especially if your CKD is not related to diabetes and your options have felt limited.

Start by asking about your eGFR trend and your urine albumin-to-creatinine ratio (uACR). These two numbers together tell your doctor a great deal about where your kidneys are headed. If your eGFR has been declining steadily, or if your uACR is elevated, those are exactly the situations where a conversation about finerenone — and when it might become available for broader use — is relevant. Ask specifically whether you might be a candidate once regulatory approvals follow these trials, and whether your care team is tracking the updated CKD guidelines expected in response to this research.

It's also worth asking whether other evidence-based kidney-protective strategies are fully in place. SGLT2 inhibitors, blood pressure control, and dietary protein adjustments each play a role in slowing CKD progression. Finerenone, if approved broadly, would likely work alongside these — not instead of them. Think of it as another layer of protection, not a replacement for what's already working.

Managing CKD Day-to-Day While Research Evolves

One of the harder realities of living with a condition like CKD is that the best available treatment today may not be the best available treatment in two years. That's actually good news — it means the science is moving — but it requires staying engaged with your care. Getting annual kidney function labs, keeping your blood pressure in the range your doctor recommends (typically under 130/80 for CKD patients), and being honest about medication adherence are unglamorous but genuinely effective ways to protect your kidneys right now.

Fluid intake matters too, though the right amount depends on your stage of CKD — another question worth asking your doctor directly, since the old advice to "drink more water" isn't universally appropriate for kidney patients. Diet adjustments — moderating sodium, sometimes potassium, and protein depending on your stage — can make a measurable difference in how quickly or slowly your eGFR declines over time. None of this is exciting. But in a condition defined by gradual change, small consistent habits carry real weight.

Maria is still waiting to hear whether finerenone will become an option for her. Her nephrologist mentioned the new trials at their last appointment — which she'd already read about — and told her to expect movement on expanded approvals within the next year or two. For the first time in a while, she left that appointment feeling like the conversation had shifted. "There's not much we can do" was no longer quite the right framing. There's more on the horizon. And for adults who've been managing CKD with limited tools, that's a meaningful change.

Common Questions

Is finerenone currently approved to treat chronic kidney disease without diabetes?

As of mid-2026, finerenone is FDA-approved specifically for CKD associated with type 2 diabetes. The three landmark trials published in June 2026 show significant benefits in non-diabetic CKD, but regulatory approval for this broader indication is pending. Ask your doctor whether you might qualify once updated approvals follow the new evidence.

What are the main risks or side effects of finerenone that adults should know about?

The most important side effect is elevated potassium in the blood (hyperkalemia), which can be serious in people with reduced kidney function. Finerenone also requires regular monitoring of kidney function and electrolytes. Your doctor will assess whether your potassium levels and eGFR are in a safe range before prescribing it and will monitor them during treatment.

How do I know if my chronic kidney disease is progressing quickly enough to warrant a specialist conversation?

Two key numbers to track are your eGFR (estimated glomerular filtration rate) and your urine albumin-to-creatinine ratio (uACR). A consistently declining eGFR over 12–24 months, or a uACR above 30 mg/g, generally warrants a nephrology referral or a more active treatment discussion. Ask your doctor to show you your trend over time, not just a single result.

Can finerenone be taken alongside other common CKD medications like SGLT2 inhibitors or ACE inhibitors?

In the clinical trials, many participants were already taking ACE inhibitors, ARBs, or SGLT2 inhibitors, and finerenone showed benefits on top of those treatments. Combination use is likely to be part of future treatment protocols, but it requires careful monitoring of kidney function and potassium. This is a decision to make with your nephrologist based on your specific lab values and medical history.